Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Curently, Dr. Feld is clinician-scientist based at the Toronto Western Hospital Liver Clinic and the McLaughlin-Rotman Centre for Global Health.
Dr. Felds research focuses on understanding treatment non-response in hepatitis C and more broadly on understanding the antiviral immune response and developing new strategies for the treatment of viral hepatitis.
Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.
J Viral Hepat. 2019 May 20;:
Ann Hepatol. 2019 Apr 25;:
Clin Liver Dis (Hoboken). 2018 Nov;12(5):125-129
Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.
J Viral Hepat. 2019 Apr 11;:
Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
Cells. 2019 Apr 05;8(4):
Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B.
Liver Int. 2019 Mar 25;:
Dig Dis Sci. 2019 Apr;64(4):1041-1049
Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure.
Cell Mol Gastroenterol Hepatol. 2019;7(2):477-479.e4
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.
J Virus Erad. 2019 Jan 01;5(1):60-66
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Scientist, Sandra Rotman Centre for Global Health, Toronto, Ontario, Canada
Research Director, Gastroenterology, Medicine/University of Toronto, Francis Family Liver Clinic - Toronto Western Hospital, Toronto, Ontario, Canada
Associate Professor of Medicine, University of Toronto, Toronto, Ontario, Canada